Penny Breeze - Publications
Thomas C, Sadler S, Breeze P, Squires H, Gillett M & Brennan A (2017)
Assessing the potential return on investment of the proposed UK NHS diabetes prevention programme in different population subgroups: an economic evaluation. BMJ Open, 7. View this article in WRRO
Breeze PR, Thomas C, Squires H, Brennan A, Greaves C, Diggle P, Brunner E, Tabak A, Preston L & Chilcott J (2017)
Cost-effectiveness of population-based, community, workplace and individual policies for diabetes prevention in the UK.. Diabetic Medicine. View this article in WRRO
Breeze PR, Thomas C, Squires H, Brennan A, Greaves C, Diggle PJ, Brunner E, Tabak A, Preston L & Chilcott J (2017)
The impact of Type 2 diabetes prevention programmes based on risk-identification and lifestyle intervention intensity strategies: a cost-effectiveness analysis.. Diabetic Medicine. View this article in WRRO
Breeze P, Squires H, Chilcott J, Stride C, Diggle PJ, Brunner E, Tabak A & Brennan A (2016)
A statistical model to describe longitudinal and correlated metabolic risk factors: the Whitehall II prospective study.. J Public Health (Oxf), 38(4), 679-687. View this article in WRRO
Thomas C, Breeze P, Strong M, Brennan A, Norman P, Cameron D & Epton T (2016)
The cost-effectiveness of an updated theory-based online health behavior intervention for new university students: U@Uni2. Journal of Public Health & Epidemiology, 8(10), 191-203. View this article in WRRO
Retracted: Impact of Type 2 diabetes prevention programmes based on risk identification and lifestyle intervention intensity strategies: a cost-effectiveness analysis. Diabetic Medicine, 33(8), 1155-1163.
Breeze P & Brennan A (2015)
Valuing Trial Designs from a Pharmaceutical Perspective Using Value-Based Pricing. Health Economics (United Kingdom), 24(11), 1468-1482. View this article in WRRO
Simpson EL, Davis S, Thokala P, Breeze PR, Bryden P & Wong R (2015)
Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective. PharmacoEconomics, 33(11), 1187-1194. View this article in WRRO
Gillett M, Brennan A, Watson P, Khunti K, Davies M, Mostafa S & Gray LJ (2015)
The cost-effectiveness of testing strategies for type 2 diabetes: a modelling study. Health Technology Assessment, 19(33), 1-80.
Strong M, Oakley JE, Brennan A & Breeze P (2015)
Estimating the Expected Value of Sample Information Using the Probabilistic Sensitivity Analysis Sample. Medical Decision Making, 35(5), 570-583. View this article in WRRO
Watson P, Brennan A, Birch H, Fang H & Petri M (2015)
An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins Lupus Cohort. Rheumatology, 54(4), 623-632.
Watson P, Preston L, Squires H, Chilcott J & Brennan A (2014)
Modelling the economics of type 2 diabetes mellitus prevention: a literature review of methods.. Appl Health Econ Health Policy, 12(3), 239-253.
Choy E, Richards S, Bowrin K, Watson P, Lloyd A, Sadosky A & Zlateva G (2010) Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective.
Conference proceedings papers
Thomas C, Watson P, Squires H, Chilcott J & Brennan A (2014)
Validation of the SPHR Diabetes Prevention Model. Value in Health, Vol. 17(7) (pp A556-A556)
Thomas C, Watson P, Greaves C, Squires H, Chilcott J & Brennan A (2014)
Layering Interventions for Type-2 Diabetes Prevention Using The Sphr Diabetes Model. Value in Health, Vol. 17(7) (pp A347-A347)
Watson P & Brennan A (2013)
The expected value of sample information from the pharmaceutical perspective under conditions of value based pricing. Value in Health, Vol. 16(3) (pp A29-A29)
Watson P & Brennan A (2012) Validation of an individual patient level simulation of the natural history of systemic Lupus erythematosus against an alternative longitudinal cohort.
2012 Operational Research Society Simulation Workshop, SW 2012 (pp 19-24)
Watson P, Brennan A, Birch H, Fang H & Petri M (2011) The Natural History and Predictive Factors of Long Term Outcomes in Systemic Lupus Erythematosus.. ARTHRITIS AND RHEUMATISM, Vol. 63(10) (pp S951-S951)